Boston Scientific Corporation $BSX Stock Holdings Increased by West Family Investments Inc.

West Family Investments Inc. raised its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 163.2% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 6,285 shares of the medical equipment provider’s stock after buying an additional 3,897 shares during the period. West Family Investments Inc.’s holdings in Boston Scientific were worth $675,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the stock. Williamson Legacy Group LLC lifted its holdings in shares of Boston Scientific by 1.1% during the second quarter. Williamson Legacy Group LLC now owns 11,760 shares of the medical equipment provider’s stock valued at $1,263,000 after purchasing an additional 123 shares during the last quarter. Schroder Investment Management Group raised its holdings in Boston Scientific by 12.7% during the 2nd quarter. Schroder Investment Management Group now owns 8,363,057 shares of the medical equipment provider’s stock worth $898,276,000 after buying an additional 940,875 shares during the period. Edgewood Management LLC purchased a new stake in Boston Scientific during the second quarter valued at about $746,655,000. Mackenzie Financial Corp boosted its holdings in shares of Boston Scientific by 107.9% in the second quarter. Mackenzie Financial Corp now owns 1,603,611 shares of the medical equipment provider’s stock worth $172,244,000 after buying an additional 832,272 shares during the period. Finally, Skandinaviska Enskilda Banken AB publ increased its position in shares of Boston Scientific by 48.7% in the second quarter. Skandinaviska Enskilda Banken AB publ now owns 2,025,153 shares of the medical equipment provider’s stock worth $217,522,000 after acquiring an additional 663,569 shares in the last quarter. 89.07% of the stock is owned by institutional investors.

Boston Scientific Price Performance

NYSE BSX opened at $101.95 on Friday. Boston Scientific Corporation has a fifty-two week low of $85.98 and a fifty-two week high of $109.50. The stock’s 50-day moving average is $99.17 and its two-hundred day moving average is $102.27. The firm has a market cap of $151.13 billion, a P/E ratio of 54.52, a price-to-earnings-growth ratio of 2.02 and a beta of 0.58. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.The business had revenue of $5.07 billion for the quarter, compared to analyst estimates of $4.97 billion. During the same quarter in the prior year, the firm posted $0.63 EPS. The firm’s revenue for the quarter was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. On average, analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. Erste Group Bank cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Friday, October 3rd. Barclays upped their price target on Boston Scientific from $133.00 to $136.00 and gave the company an “overweight” rating in a research report on Thursday, October 2nd. Wall Street Zen upgraded Boston Scientific from a “hold” rating to a “buy” rating in a report on Saturday, October 11th. UBS Group boosted their price objective on shares of Boston Scientific from $135.00 to $140.00 and gave the company a “buy” rating in a research report on Thursday, October 23rd. Finally, BTIG Research reiterated a “buy” rating and issued a $132.00 target price on shares of Boston Scientific in a research report on Friday, November 21st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, Boston Scientific currently has an average rating of “Buy” and an average target price of $123.77.

Insider Activity at Boston Scientific

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business’s stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $98.47, for a total value of $4,923,500.00. Following the completion of the sale, the executive vice president directly owned 178,342 shares in the company, valued at approximately $17,561,336.74. The trade was a 21.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Ellen M. Zane sold 12,891 shares of the company’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the sale, the director directly owned 24,134 shares of the company’s stock, valued at approximately $2,371,889.52. This represents a 34.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 175,782 shares of company stock worth $17,742,314. Corporate insiders own 0.50% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.